Trevi Therapeutics, INC

Trevi Therapeutics announced Q1 2026 financial results, highlighting progress in chronic cough indications and a significant capital raise extending cash runway into 2030.

Trevi Therapeutics has priced an underwritten public offering of 11.6 million shares of common stock at $13.00 per share to raise approximately $150 million in gross proceeds.

Trevi Therapeutics announced positive financial results for Q4 and full-year 2025, secured FDA alignment for its Haduvio Phase 3 program, and plans to initiate multiple clinical trials in 2026.

Trevi Therapeutics, Inc. announced the appointment of David Hastings, a seasoned biopharmaceutical executive, as its new Chief Financial Officer, effective January 6, 2026.

Trevi Therapeutics announced its third quarter 2025 financial results and provided updates on its Haduvio clinical programs, including plans for a Phase 3 initiation in early 2026.

Trevi Therapeutics announces the resignation of CFO Lisa Delfini, with CEO Jennifer L. Good assuming interim principal financial officer duties.

Trevi Therapeutics announced its third-quarter 2025 financial results, highlighting positive Phase 2b CORAL trial data for Haduvio in IPF chronic cough and progress across its clinical pipeline.

Trevi Therapeutics announced positive Phase 2b and Phase 2a clinical trial results for Haduvio in chronic cough, extending its cash runway into 2029.

Trevi Therapeutics reports its Q1 2025 financial results, showcasing ongoing clinical trial progress for Haduvio in treating chronic cough related to IPF, non-IPF ILD, and RCC.

Trevi Therapeutics reports a net loss of $13.2 million for the third quarter of 2024, while advancing its clinical programs for Haduvio.

Trevi Therapeutics reports a net loss of $23.3 million for the first half of 2024, while advancing clinical trials for Haduvio.

Trevi Therapeutics reports a net loss of $10.9 million for the first quarter of 2024, while advancing its clinical programs for Haduvio.

Trevi Therapeutics' 10-K filing highlights positive clinical trial results for Haduvio and outlines the company's strategy for future development and commercialization.

Trevi Therapeutics' 10-K filing details its capital structure, stock information, and regulatory environment, emphasizing its focus on developing Haduvio for chronic cough and pruritus.

Director Edward T. Mathers was granted 35,000 nonstatutory stock options in Trevi Therapeutics, Inc.

David P. Meeker, a Director at Trevi Therapeutics, Inc., acquired 35,000 stock options with an exercise price of $13.45.

Trevi Therapeutics, Inc. reports that Director Anne Vanlent was granted stock options for 35,000 shares.

Michael Heffernan, a Director at Trevi Therapeutics, Inc., acquired 35,000 stock options with an exercise price of $13.45, vesting on June 3, 2026.

Trevi Therapeutics' Chief Financial Officer, David C. Hastings, was granted 375,000 stock options with an exercise price of $11.21, vesting over four years.

Christopher Galletta, Trevi Therapeutics' Controller, exercised stock options and acquired common stock under a pre-arranged plan.

Trevi Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 3, 2026, and is seeking shareholder approval to increase its authorized common stock and amend its stock incentive plan.

Trevi Therapeutics has scheduled its 2025 Annual Meeting for June 11, 2025, and is seeking stockholder votes on director elections, auditor ratification, executive compensation, and an amendment to the stock incentive plan.

Trevi Therapeutics is holding its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to vote on key proposals including director elections and an amendment to the company's stock incentive plan.

Trevi Therapeutics is holding its annual meeting of stockholders on June 13, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its auditor.

Trevi Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to elect directors and ratify the appointment of its independent accounting firm.

New Enterprise Associates reports a change in beneficial ownership percentage in Trevi Therapeutics due to an increase in the issuer's total outstanding shares.

New Enterprise Associates (NEA) has filed an amendment to correct beneficial ownership disclosures for Trevi Therapeutics, Inc., reflecting prior warrant exercises.

New Enterprise Associates (NEA) entities and affiliated managers have reported a decrease in their beneficial ownership of Trevi Therapeutics, Inc. common stock to 12.0% due to an increase in the total shares outstanding.

New Enterprise Associates (NEA) has filed an Amendment No. 6 to its Schedule 13D, reporting a decrease in its beneficial ownership percentage of Trevi Therapeutics, Inc. common stock to 15.0% from a previously higher percentage, primarily due to an increase in the total number of outstanding shares.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 6.3% of Trevi Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Trevi Therapeutics Inc. due to an internal realignment.

Rubric Capital Management LP and David Rosen have reported a reduced beneficial ownership stake of 2.94% in Trevi Therapeutics, Inc. as of December 31, 2025.

FMR LLC and Abigail P. Johnson have reported a 5.1% beneficial ownership stake in Trevi Therapeutics Inc. common stock as of December 31, 2025.

The Vanguard Group reported a 5.01% beneficial ownership stake in Trevi Therapeutics Inc. common stock as of December 31, 2025.

Viking Global Investors LP and its affiliates have filed an amended Schedule 13G, disclosing a 4.2% beneficial ownership stake in Trevi Therapeutics, Inc. as of September 30, 2025.